logo
logo

Gt Biopharma Announces $16 Million In Warrant Exercise Proceeds

Gt Biopharma Announces $16 Million In Warrant Exercise Proceeds

07/28/21, 12:01 PM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgbeverly hills
Money raised
$16 million
GT Biopharma, Inc. (NASDAQ: GTBP), an immuno-oncology company focused on innovative therapies based on the Company's proprietary NK cell engager (TriKETM) technology platform is pleased to announce the company has raised over $16 million in proceeds from the exercise of warrants. The warrants were issued as part of the $27 million financing that closed in February 2021.

Company Info

Company
Gt Biopharma
Location
beverly hills, california, united states
Additional Info
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based our proprietary TriKETM NK cell engager platform. Our TriKETM platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKETM technology. For more information, please visit www.gtbiopharma.com.